Take Homes in Multiple Myeloma

Take Homes in Multiple Myeloma

Source: Healio Interview
Disclosures: Richardson reports consulting for and/or receiving research support from AstraZeneca, Celgene/BMS, GSK, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio and Takeda.
June 22, 2022
1 min watch
Save

VIDEO: DETERMINATION study produces data on racial disparities in multiple myeloma

Source: Healio Interview
Disclosures: Richardson reports consulting for and/or receiving research support from AstraZeneca, Celgene/BMS, GSK, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio and Takeda.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Paul Richardson, MD, director of clinical research at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses the phase III DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.

Richardson highlights the fact that despite the difference in progression-free survival between the early transplant and delayed transplant arms of the study, there was no overall impact on overall survival gain, which he believes to be a highly important finding.

Richardson also discussed data showing that African-American patients may have an option to keep transplants in reserve.

Reference:

  • Richardson P, et al. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.